{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:47:05Z","timestamp":1771350425815,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004006","name":"Istanbul University Scientific Research Projects Unit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.yebeh.2021.107980","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T13:45:26Z","timestamp":1620049526000},"page":"107980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Predictors of successful valproate withdrawal in women with epilepsy"],"prefix":"10.1016","volume":"119","author":[{"given":"Arife \u00c7imen","family":"Atalar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nermin G\u00f6rkem","family":"\u015eirin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerses","family":"Bebek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bet\u00fcl","family":"Baykan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.yebeh.2021.107980_b0005","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: From molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.yebeh.2021.107980_b0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eplepsyres.2015.11.012","article-title":"Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate","volume":"119","author":"Chowdhury","year":"2016","journal-title":"Epilepsy Res"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2021.107980_b0015","first-page":"s1","article-title":"Valproate: life-saving, life-changing","volume":"18","author":"Thomas","year":"2018","journal-title":"Clin Med (Lond)"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107980_b0020","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107980_b0025","unstructured":"European Medicines Agency Assessment Report. Procedure under Article 31 of Directive 2001\/83\/EC resulting from pharmacovigilance data. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Valproate_and_related_substances_31\/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee\/WC500177352.pdf; 2015 (accessed April 10, 2015)."},{"key":"10.1016\/j.yebeh.2021.107980_b0030","unstructured":"European Medicines Agency. PRAC recommends new measures to avoid valproate exposure in pregnancy. EMA\/67672\/2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2018\/02\/WC500243555.pdf; 2018 [ Accessed 2 March 2018]."},{"issue":"23","key":"10.1016\/j.yebeh.2021.107980_b0035","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","article-title":"Valproic acid monotherapy in pregnancy and major congenital malformations","volume":"362","author":"Jentink","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.yebeh.2021.107980_b0040","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/pds.4881","article-title":"Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries","volume":"28","author":"Charlton","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"10.1016\/j.yebeh.2021.107980_b0045","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/pds.4897","article-title":"Prescription of antiepileptic medicines including valproate in pregnant women: A study in three European countries","volume":"28","author":"Hurault\u2010Delarue","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.yebeh.2021.107980_b0050","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107980_b0055","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1111\/ane.12216","article-title":"Low-dose sodium valproate in the treatment of idiopathic generalized epilepsies","volume":"129","author":"Mir\u00f3","year":"2014","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1016\/j.yebeh.2021.107980_b0060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: A prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.yebeh.2021.107980_b0065","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/epi.13007","article-title":"Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy","volume":"56","author":"Wood","year":"2015","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107980_b0070","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.yebeh.2021.107980_b0075","doi-asserted-by":"crossref","unstructured":"Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev, 30. 2014(10):CD010236.","DOI":"10.1002\/14651858.CD010236.pub2"},{"key":"10.1016\/j.yebeh.2021.107980_b0080","doi-asserted-by":"crossref","unstructured":"Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database of Systematic Reviews 2017; 12 (12): CD011412. 10.1002\/ 14651858.CD011412.pub32.","DOI":"10.1002\/14651858.CD011412.pub3"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107980_b0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/epi.16407","article-title":"Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: Implications on seizure outcome","volume":"61","author":"Cerulli Irelli","year":"2020","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2021.107980_b0090","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107980_b0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0987-7053(02)00343-X","article-title":"Eyelid myoclonia with absences: an overlooked epileptic syndrome?","volume":"32","author":"Striano","year":"2002","journal-title":"Neurophysiol Clin"},{"key":"10.1016\/j.yebeh.2021.107980_b0100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cnp.2017.07.002","article-title":"A revised glossary of terms most commonly used by clinical electroencephalographers and updated proposal for the report format of the EEG findings. Revision 2017","volume":"2","author":"Kane","year":"2017","journal-title":"Clin Neurophysiol Pract"},{"key":"10.1016\/j.yebeh.2021.107980_b0105","doi-asserted-by":"crossref","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51(6) :1069-77.","DOI":"10.1111\/j.1528-1167.2009.02397.x"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107980_b0110","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/epi.13732","article-title":"Remission in epilepsy: how long is enough?","volume":"58","author":"Sillanp\u00e4\u00e4","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107980_b0115","article-title":"Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience-a European perspective. [published online ahead of print, 2020 Apr 1]","author":"Toledo","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2021.107980_b0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bmj.290.6471.815","article-title":"Which drug for the adult epileptic patient: phenytoin or valproate?","volume":"290","author":"Turnbull","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"7","key":"10.1016\/j.yebeh.2021.107980_b0125","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp.48.7.639","article-title":"A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy","volume":"48","author":"Callaghan","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.yebeh.2021.107980_b0130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199209103271104","article-title":"A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults: The Department of the Veteran Affairs Epilepsy Cooperative Study Group","volume":"327","author":"Mattson","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107980_b0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/jnnp.58.1.44","article-title":"Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial","volume":"58","author":"Heller","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107980_b0140","doi-asserted-by":"crossref","unstructured":"Tudur Smith C, Marson AG, Williamson PR. Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 2001; 4:CD001769. Update in: Cochrane Database Syst Rev 2013;8:CD001769.","DOI":"10.1002\/14651858.CD001769"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107980_b0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1468-1331.2007.02003.x","article-title":"VIPe Study Group. An observational study of first-line valproate monotherapy in focal epilepsy","volume":"15","author":"Jedrzejczak","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2021.107980_b0150","unstructured":"European Medicines Agency. CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/valproate-related-substances#all-documents-section."},{"key":"10.1016\/j.yebeh.2021.107980_b0155","doi-asserted-by":"crossref","first-page":"116940","DOI":"10.1016\/j.jns.2020.116940","article-title":"Valproate impact and sex-dependent seizure remission in patients with idiopathic generalized epilepsy","volume":"415","author":"Cerulli Irelli","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2021.107980_b0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.seizure.2020.09.008","article-title":"Risk-benefit assessment of treatment of epileptic women of childbearing age with valproic acid","volume":"82","author":"Qu\u00edlez","year":"2020","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.yebeh.2021.107980_b0165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/00325481.2019.1663126","article-title":"Drug-responsive versus drug-refractory mesial temporal lobe epilepsy: a single-center prospective outcome study","volume":"131","author":"Stefanatou","year":"2019","journal-title":"Postgrad Med"},{"key":"10.1016\/j.yebeh.2021.107980_b0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.seizure.2018.07.011","article-title":"Evaluation of long-term antiepileptic drug use in patients with temporal lobe epilepsy: Assessment of risk factors for drug resistance and polypharmacy","volume":"61","author":"Bj\u00f8rke","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107980_b0175","doi-asserted-by":"crossref","unstructured":"Gilioli I, Vignoli A, Visani E, Casazza M, Canafoglia L, Chiesa V, et al. Focal epilepsies in adult patients attending two epilepsy centers: classification of drug-resistance, assessment of risk factors, and usefulness of \u201cnew\u201d antiepileptic drugs. Epilepsia 2012; 53 (4):733-40.","DOI":"10.1111\/j.1528-1167.2012.03416.x"},{"key":"10.1016\/j.yebeh.2021.107980_b0180","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.wneu.2016.12.074","article-title":"Prevalence and incidence of drug-resistantm mesial temporal lobe epilepsy in the United States","volume":"99","author":"Asadi-Pooya","year":"2017","journal-title":"World Neurosurg"},{"issue":"4","key":"10.1016\/j.yebeh.2021.107980_b0185","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","article-title":"Marson AG (2012) Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial","volume":"11","author":"Bonnett","year":"2012","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.yebeh.2021.107980_b0190","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1212\/01.wnl.0000248189.93630.4f","article-title":"New-onset temporal lobe epilepsy in children: lesion on MRI predicts poor seizure outcome","volume":"67","author":"Spooner","year":"2006","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.yebeh.2021.107980_b0195","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1212\/WNL.57.12.2259","article-title":"Response to first drug trial predicts outcome in childhood temporal lobe epilepsy","volume":"57","author":"Dlugos","year":"2001","journal-title":"Neurology"},{"issue":"2-3","key":"10.1016\/j.yebeh.2021.107980_b0200","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.eplepsyres.2009.03.001","article-title":"Prognosis of patients with mesial temporal lobe epilepsy due to hippocampal sclerosis","volume":"85","author":"Varoglu","year":"2009","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.yebeh.2021.107980_b0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1528-1167.2009.02042.x","article-title":"Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959\u20132009","volume":"50","author":"Shorvon","year":"2009","journal-title":"Epilepsia"},{"issue":"9566","key":"10.1016\/j.yebeh.2021.107980_b0210","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.yebeh.2021.107980_b0215","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/epi.13702","article-title":"Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies","volume":"58","author":"Gesche","year":"2017","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.yebeh.2021.107980_b0220","doi-asserted-by":"crossref","first-page":"e2519","DOI":"10.1212\/WNL.0000000000010644","article-title":"Patterns and prognostic markers for treatment response in generalized epilepsies","volume":"95","author":"Gesche","year":"2020","journal-title":"Neurology"},{"issue":"Issue 22, Part 2","key":"10.1016\/j.yebeh.2021.107980_b0225","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/01.wnl.0000313148.34629.1d","article-title":"Myoclonic seizures subside in the fourth decade in juvenile myoclonic epilepsy","volume":"70","author":"Baykan","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107980_b0230","doi-asserted-by":"crossref","unstructured":"Martinez-Juarez IE, Alonso ME, Medina MT, Dur\u00f3n RM, Bailey JN, L\u00f3pez-Ruiz M, et al. Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up. Brain 2006;129 (Pt 5):1269-80.","DOI":"10.1093\/brain\/awl048"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107980_b0235","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/jnnp.70.2.240","article-title":"Clinical factors of drug resistance in juvenile myoclonic epilepsy","volume":"70","author":"Gelisse","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107980_b0240","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.yebeh.2012.06.036","article-title":"Lifetime prognosis of juvenile myoclonic epilepsy","volume":"28","author":"Baykan","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107980_b0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.seizure.2010.10.004","article-title":"Prognosis of juvenile myoclonic epilepsy is related to endophenotypes","volume":"20","author":"Guaranha","year":"2011","journal-title":"Seizure"},{"issue":"10","key":"10.1016\/j.yebeh.2021.107980_b0250","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1007\/s00415-019-09457-z","article-title":"Discontinuing antiepileptic drugs in long-standing idiopathic generalised epilepsy","volume":"266","author":"Vorderw\u00fclbecke","year":"2019","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.yebeh.2021.107980_b0255","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1474-4422(17)30114-X","article-title":"Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis","volume":"16","author":"Lamberink","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107980_b0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.yebeh.2014.12.042","article-title":"Eyelid myoclonia seizures in adults: An alternate look at the syndrome paradox","volume":"45","author":"Nar Senol","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107980_b0265","doi-asserted-by":"crossref","DOI":"10.1111\/epi.15157","article-title":"Eyelid myoclonia with absences: Electroclinical features and prognostic factors","author":"Giuliano","year":"2019","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.yebeh.2021.107980_b0270","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/j.1528-1167.2012.03723.x","article-title":"The prognosis of idiopathic generalized epilepsy","volume":"53","author":"Seneviratne","year":"2012","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2021.107980_b0275","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.neurol.2020.03.018","article-title":"Genetic\/idiopathic generalized epilepsies: Not so good as that!","volume":"176","author":"Nilo","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.yebeh.2021.107980_b0280","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.seizure.2017.05.011","article-title":"Juvenile myoclonic epilepsy as a spectrum disorder: A focused review","volume":"49","author":"Baykan","year":"2017","journal-title":"Seizure"},{"issue":"13","key":"10.1016\/j.yebeh.2021.107980_b0285","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181b9c86f","article-title":"Juvenile myoclonic epilepsy 25 years after seizure onset: a population-based study","volume":"73","author":"Camfield","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2021.107980_b0290","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ene.14142","article-title":"Epidemiology and outcome of idiopathic generalized epilepsy in adults","volume":"27","author":"Gesche","year":"2020","journal-title":"Eur J Neurol"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2021.107980_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2019.06.031","article-title":"Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study","volume":"98","author":"Bosak","year":"2019","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:39:06Z","timestamp":1761503946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021002146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":59,"alternative-id":["S1525505021002146"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107980","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of successful valproate withdrawal in women with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107980"}}